Latest Shareholder Equity News

Everest Metals has been accepted into the US Defence Industrial Base Consortium, unlocking strategic collaboration and funding opportunities for its Mt Edon Rubidium Project in Western Australia. This milestone advances Australia’s first commercial rubidium production, addressing critical global supply shortages.

EMVision Medical Devices has secured a $5 million non-dilutive government grant to accelerate global commercialisation of its innovative First Responder portable brain scanner, aimed at revolutionising pre-hospital stroke and brain injury care.

Tempest Minerals has completed a pro-rata entitlement offer, raising over $600,000 to fund exploration in Western Australia, though a significant shortfall remains to be allocated.

Caravel Minerals has locked in a $15 million loan facility to fund the critical Definitive Feasibility Study for its flagship Caravel Copper Project, advancing the path to development without diluting shareholder equity.

Mirrabooka Investment Limited has successfully closed its $85 million entitlement offer, which was oversubscribed, prompting a scale back of Top-Up Facility applications.

I Synergy Group Limited has announced a renounceable entitlement offer aiming to raise approximately $1 million to fund new projects and operational growth. The offer is fully underwritten and open to shareholders across multiple Asia-Pacific markets.

ANZ Group Holdings Limited has updated its interim dividend details, confirming an 83-cent payout per share, partially franked at 70%, payable on July 1, 2025. The bank also outlined its Dividend Reinvestment and Bonus Security Plans with shares priced at AUD 28.89.

Surefire Resources NL has launched a non-renounceable entitlement offer aiming to raise approximately A$3.87 million to advance its gold and copper projects in Western Australia. The offer includes new shares, bonus shares, and options, targeting eligible shareholders in Australia and New Zealand.

AFT Pharmaceuticals reported a 6% revenue increase to NZ$208 million in FY25, driven by strong ANZ growth and expanding international presence. The company targets NZ$300 million revenue by FY27 amid ongoing R&D and new product launches.

Noxopharm Limited has raised nearly $2.5 million by selling its entire stake in Nyrada Inc, providing non-dilutive capital to advance its HERACLES clinical trial and expand its research pipeline.

Marimaca Copper Corp reported a net loss of $2.25 million for Q1 2025, maintaining solid liquidity while managing risks tied to a significant receivable under liquidation proceedings.

Macquarie Group Limited has posted a 5% increase in net profit for FY2025, driven by strong asset management and banking growth, while advancing its sustainability and digital innovation agenda.